Drugs / EW-A-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00080392 | Mar 2004 → Dec 2011 | intermittent vascular claudication | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EW-A-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080392 ↗ |
| Action | Activate | “increase expression of the VEGF-A gene” NCT00080392 ↗ |
| Modality | Other / unclassified | “The investigational agent is a circle of genetic material (plasmid DNA)” NCT00080392 ↗ |
| Route | Intramuscular | “The study agent will be delivered by injection into leg muscle during a single session.” NCT00080392 ↗ |